CLINICAL ROLE -
Clinical Perspectives on GPRC5D-Targeted CAR T-Cell Therapy for Multiple Myeloma
Omar Nadeem, MD, discusses positive outcomes associated with GPRC5D-targeted CAR T-cell therapy.
Long-Term Follow-Up of Ibrutinib in CLL/SLL: Insights and Outcomes
Follow-up data reveal 10-year impact of ibrutinib in treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).
Reni-Cel Single Infusion Gene Editing Therapy Demonstrates Positive Results in Patients With Sickle Cell Disease
These findings build off research from March 2023 that demonstrated efficacy and safety of renizgamglogene autogedtemcel in patients with sickle cell disease.
Acalabrutinib Combination Treatment Improves Progression-Free Survival in Patients With Previously Untreated MCL
Compared with standard of care chemoimmunotherapy, acalabrutinib with bendamustine and rituximab reduced risk of death or disease by approximately 27%.
Asciminib Shows Superior Efficacy, Favorable Safety in Patients With Newly Diagnosed Chronic Myeloid Leukemia
Asciminib demonstrated stronger efficacy, safety, and tolerability, as well as less adverse events in patients compared with those who received investigator-selected standard-of-care tyrosine kinase inhibitors.
